Citation Impact
Citing Papers
Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease
2009
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
2015
Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents
2009
Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience
2011
Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment
2009
β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase
2005 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
2001
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Breast cancer
2016 Standout
Thyroid cancer
2016 Standout
Targeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
2020
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
2000
Osteoporosis: now and the future
2011 Standout
Bone cancer pain: Causes, consequences, and therapeutic opportunities
2013
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies
2009
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
2014
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Evaluation of bone metabolic markers in breast cancer with bone metastasis
2001
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
2011
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
2012
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm
2002 Nature
Biomedical applications of bisphosphonates
2013
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study
2010
Bisphosphonates in breast cancer
2005
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
New platinum(II) complexes conjugated at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: Design, synthesis, structure–activity relationships and biological evaluation
2013
Bladder cancer
2016 Standout
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
2011
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
The evolving role of bisphosphonates
2001
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials
2013
Antiresorptives and Osteonecrosis of the Jaw
2012
Paradoxical roles of the immune system during cancer development
2006 Standout
Microenvironmental regulation of metastasis
2008 Standout
Néstor–Guillermo progeria syndrome: A novel premature aging condition with early onset and chronic development caused by BANF1 mutations
2011
A sensitive amperometric immunosensor for carcinoembryonic antigen detection with porous nanogold film and nano-Au/chitosan composite as immobilization matrix
2007
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Future directions of bone-targeted therapy for metastatic breast cancer
2010
β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
2007 StandoutNobel
Mechanisms of Bone Metastasis
2004 Standout
MicroRNA maturation: stepwise processing and subcellular localization
2002 Standout
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
2008
The Hallmarks of Aging
2013 Standout
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Messenger-RNA-binding proteins and the messages they carry
2002
Bone metastases from differentiated thyroid carcinoma
2008
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
2012
Biochemical Markers of Bone Metabolism: An Overview
1997
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
2012
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Ablation of Skeletal Metastases: Current Status
2010
Skeletal and extraskeletal actions of denosumab
2012
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
2012
Long noncoding RNAs: functional surprises from the RNA world
2009 Standout
Unmasking senescence: context-dependent effects of SASP in cancer
2019
Novel approaches to target the microenvironment of bone metastasis
2021
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment
2008
Perioperative Antibiotic Regimen in Rats Treated With Pamidronate Plus Dexamethasone and Subjected to Dental Extraction: A Study of the Changes in the Jaws
2011
Prostate cancer invasion and metastasis: insights from mining genomic data
2013
N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions
2015 StandoutNature
Gene expression in human neural stem cells: effects of leukemia inhibitory factor
2003
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Targeted delivery to bone and mineral deposits using bisphosphonate ligands
2015
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
2012
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis
2012
Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes
2016 Standout
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain
2003
Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid
2005
Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth
2004
Mechanisms of osteolytic bone metastases in breast carcinoma
2003
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
2002
Pain regulation by non-neuronal cells and inflammation
2016 StandoutScience
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
2003
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
2001 Standout
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
2003 StandoutScience
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity
2007
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
2008
Bisphosphonates for Treatment and Prevention of Bone Metastases
2005
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
Skeletal complications of malignancy
1997 Standout
Guidelines for the management of thyroid cancer
2014 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
2009
Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
2008
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
2007
A systematic review of the role of bisphosphonates in metastatic disease
2004
Works of Luís Costa being referenced
Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function
2001
Targeting bone metastases in prostate cancer: improving clinical outcome
2015
Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer
2015
Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System
2011
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
2013
Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations
2012
Markers of bone resorption in patients treated with pamidronate
1998
Effect of bisphosphonates on pain and quality of life in patients with bone metastases
2009
Impact of skeletal complications on patients’ quality of life, mobility, and functional independence
2008
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
2007
Biochemical markers and skeletal metastases
2000
Bone markers in the management of metastatic bone disease
2001
Anticancer evidence for zoledronic acid across the cancer continuum
2011
Consensus on the utility of bone markers in the malignant bone disease setting
2011
Bone metastases
2020
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
2019
Bisphosphonates: Reducing the risk of skeletal complications from bone metastasis
2007
Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes
2013
Biochemical markers of bone turnover in patients with metastatic bone disease
1995
Biochemical Markers and Skeletal Metastases
2003
Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status
2002
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
2010
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
2011
Serum tumor markers in metastatic breast cancer comparative study between CEA, CA-15.3 and MCA
1998
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
2012
Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status
2002
Biochemical markers and skeletal metastases.
2003
Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
2001
Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.
2010